<DOC>
	<DOCNO>NCT00954746</DOCNO>
	<brief_summary>The purpose study AUX-CC-860 ass durability response AA4500 treatment regimen . This study also evaluate long-term safety progression disease joint .</brief_summary>
	<brief_title>Longterm Observational Study Subjects Treated With AA4500 AUX-CC-854 , 856 , 857 , 858 &amp; 859</brief_title>
	<detailed_description>Phase 3 non-treatment study Year 2 Year 5 year follow-up subject receive AA4500 9-month open-label study ( AUX-CC-854 AUX-CC-856 ) 12-month double-blind open-label extension study ( AUX-CC-857/AUX-CC-858 AUX-CC-859 ) . After completion one mention study , subject enrol follow calendar year 4 consecutive year least 6 month consecutive visit .</detailed_description>
	<mesh_term>Dupuytren Contracture</mesh_term>
	<criteria>To eligible study subject : Have receive least one injection AA4500 one Auxilium sponsor study ( AUXCC854 , AUXCC856 , Studies AUXCC857/AUXCC858 , AUXCC859 ) least one fixedflexion contracture measurement treatment AA4500 Be able willing comply yearly assessment outline protocol , determine investigator Voluntarily sign date inform consent agreement approve Institutional Review Board/Independent Ethics Committee ( IRB/IEC )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Advanced Dupuytren 's Disease</keyword>
	<keyword>Muscular Diseases</keyword>
	<keyword>Musculoskeletal Diseases</keyword>
	<keyword>Contracture Joint Diseases</keyword>
	<keyword>Connective Tissue Diseases</keyword>
	<keyword>Dupuytren 's Contracture</keyword>
</DOC>